# Pangea Biomed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pangea-biomed

- Industry: Healthcare
- Headquarters: Tel Aviv, Israel
- Website: www.pangeabiomed.com
- Total disclosed funding: $12M
- Latest round: Seed (Dec 15, 2022)
- Investors on record: 1

## About

Based in Tel Aviv, Israel, and founded in 2018 and headed by Tuvik Bekar as CEO, Pangea Biomed Ltd. is a provider of Oncology through Computational Transcriptomics. In April 2022, Pangea Biomed Ltd. raised USD 7 million in seed funding led by new investor NFX.

The firm matches the right patient with the right therapy by studying the gene group behavior and developing gene social graphs. The company offers an ENLIGHT platform by combining ML and RNA-sequencing to offer cancer treatment. The firms offer AI-driven precision drug development products namely ENLIGHT|Lens and it also offers ENLIGHT matching score (EMS) which helps in predictive cancer care for specific patients.

The company will use the April 2022 funding to grow its research and development team, also expand its partnerships and commercial collaborations.

## Funding rounds

- Seed, Dec 15, 2022, $5M — NFX
- Seed, Apr 7, 2022, $7M — NFX

## Investors

- NFX (https://capitalatlas.ai/funds/nfx) — Seed